BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoffman KL. From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia. Front Psychiatry 2021;12:682611. [PMID: 34290632 DOI: 10.3389/fpsyt.2021.682611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Setién-suero E, Ayesa-arriola R, Peña J, Crespo-facorro B, Ojeda N. Longitudinal effects of cannabis use on attentional processes in patients with first episode of psychosis. Schizophrenia Research 2022;244:71-80. [DOI: 10.1016/j.schres.2022.05.011] [Reference Citation Analysis]
2 Hoffman KL, Cano-Ramírez H. Pediatric neuropsychiatric syndromes associated with infection and microbiome alterations: clinical findings, possible role of the mucosal epithelium, and strategies for the development of new animal models. Expert Opin Drug Discov 2022. [PMID: 35543072 DOI: 10.1080/17460441.2022.2074396] [Reference Citation Analysis]
3 Stark T, Di Martino S, Drago F, Wotjak CT, Micale V. Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. Pharmacol Res 2021;174:105938. [PMID: 34655773 DOI: 10.1016/j.phrs.2021.105938] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]